Findings

What do systematic reviews say?

320 questions · 333 findings · 159 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 104 · 31.2%GRADE not reported 44 · 13.2%Very low 66 · 19.8%Low 57 · 17.1%Moderate 45 · 13.5%High 17 · 5.1%

C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Low

Nanofiltered C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Intervention vs usual care

Quality of life ‐ CAT · COPD and at least one other long‐term condition

1 finding from 1 review

Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
Low

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1652 participants
High

Reslizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Mepolizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

Intervention vs usual care

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · COPD and at least one other long‐term condition

1 finding from 1 review

Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE

QoL · patients with schizophrenia

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 132 participants
Very low

Reslizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Berotralstat vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Moderate

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Low

Avoralstat vs placebo

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 93 participants
Moderate

Acupuncture vs sham

Quality of life SF‐36 bodily pain score (0‐100, lower score = more disability) · adults with neuropathic pain

1 finding from 1 review

Acupuncture for neuropathic pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

Oral steroids vs placebo

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Electromagnetic field treatment vs placebo

Quality of life SF‐36 item Scale from: 0 to 100 (Lower scores mean worse quality) · patients with osteoarthritis

1 finding from 1 review

Electromagnetic fields for treating osteoarthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 145 participants
Moderate

Intranasal steroid spray vs placebo

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Acupuncture combined with other active therapy vs other active therapy

Quality of life FACT/the GOG‐Ntx questionnaire scores (0 ‐ 100, lower score = better) · adults with neuropathic pain

1 finding from 1 review

Acupuncture for neuropathic pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 104 participants
Low

DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies

Quality of life Assessed by LIS (scale from: 0 to 48, better indicated by a lower score) · adults with anxiety disorders

It is very uncertain whether DCS and cognitive and behavioural therapies changes quality of life Assessed by LIS (scale from: 0 to 48, better… compared with placebo and cognitive and behavioural therapies (very low certainty).

1 finding from 1 review

Augmentation of cognitive and behavioural therapies (CBT) with d‐cycloserine for anxiety and related disorders 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Very low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Moderate